Replimune Group, Inc. (Nasdaq: REPL) has priced an underwritten public offering of common stock and pre-funded warrants, with aggregate gross proceeds expected to reach approximately $150 million, according to a company statement.

The offering includes 9,701,490 shares of common stock at $12.06 per share. In addition, pre-funded warrants to purchase 2,736,340 shares were offered to certain investors at $12.0599 per warrant, reflecting the share price minus the $0.0001 exercise price per warrant. All securities are being sold by Replimune.

The offering was expected to close on Aug. 11, 2026, subject to customary closing conditions. Leerink Partners, J.P. Morgan, and Cantor are serving as bookrunning managers.

The securities are being offered under a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission on May 23, 2025, and amended on Nov. 6, 2025.

Replimune is a biotechnology company based in Woburn, Massachusetts, focused on oncolytic immunotherapies. Its product Tudriqev received accelerated approval from the U.S. Food and Drug Administration for use in combination with nivolumab to treat adults with advanced melanoma who experienced disease progression on a PD-1 antibody-based regimen.